NEW YORK (GenomeWeb) – GeneNews reported today that its third quarter revenues fell 51 percent as the company is changing how it bills for its ColonSentry colorectal cancer blood test and other diagnostics.

For the three-month period ended Sept. 30, GeneNews' revenues fell to $54,290 from $111,103 in the year-ago quarter. In a statement, GeneNews Chairman and CEO James Howard-Tripp called the revenue results "disappointing and reflective of the changes we are currently making in our billing processes."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.